Resistance in BRAF and KRAS Mutant Cancers - by Ryan Corcoran, MD, PhD
Resistance in BRAF and KRAS Mutant Cancers
Adaptive resistance in BRAF- and KRAS-mutated colorectal cancer
Mitigating resistance in KRAS-driven cancers
Clinical targeting of adaptive resistance in colorectal cancer
BRAF and RAS Mutation Status in Colorectal Cancer
Clarifying the mechanism of EGFR inhibition in KRAS G13D colorectal cancer
Resistance to MAPK pathway inhibition in BRAF mutant colorectal cancers
Survival Differences in KRAS/BRAF Mutations in mCRC
Mechanisms of acquired resistance to KRAS G12C inhibition in cancer
Colorectal Cancer with acquired resistance to EGFR antibodies: How to manage?
BRAF Mutations Across Cancers
What is the optimal therapy for BRAF mutant metastatic colorectal cancer?
Case 3: KRAS-Mutated Metastatic Colon Cancer
MOA Animation: Melanoma BRAF Inhibition
KRAS G12C Inhibitors: Acquired Resistance and Combo Strategies
How to approach the patient with a BRAF mutant tumor
Updates on biomarkers of resistance to CRC treatment
We're Finally Beginning to Crack the KRAS Nut in Colorectal Cancer
CtDNA KRAS Mutation Levels and Outcomes in Non-Resectable Pancreatic Cancer